Zymeworks ZYME Operating lease right-of-use assets amortization expense
Operating lease right-of-use assets amortization expense at other companies
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zymeworks's operating lease right-of-use assets amortization expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zymeworks's operating lease right-of-use assets amortization expense?
- Zymeworks (ZYME) reported operating lease right-of-use assets amortization expense of $1.71M in Q1 2026.
- How has Zymeworks's operating lease right-of-use assets amortization expense changed year-over-year?
- Zymeworks's operating lease right-of-use assets amortization expense increased by 141.6% year-over-year, from $707K to $1.71M.
- What is the long-term trend for Zymeworks's operating lease right-of-use assets amortization expense?
- Over 3 years (2022 to 2025), Zymeworks's operating lease right-of-use assets amortization expense has grown at a -10.8% compound annual growth rate (CAGR), from $4.77M to $3.39M.
- What does operating lease right-of-use assets amortization expense mean?
- The periodic expense recognized for the amortization of right-of-use assets associated with operating leases. This reflects the systematic consumption of the economic benefits derived from leased office, laboratory, or facility space over the lease term.